MolProbity Ramachandran analysis

MolProbity Ramachandran analysis
1M1X, model 1
General case
180
Isoleucine and valine
180
BA 549
688CYS
LYS
B 409 GLU
B 680 TYR
571
THR
BA 199
GLN
70ARG
SER
A B491
517
LEU
BA 76
ASP
Psi
62 ASN
SER
AA 659
A 905 THR
B 558 CYS
B 377 ASN
B 79 GLN
B 576 SER
A
B 910
172 ASN
ALA
B 546 ASP
A 194 LYS
A 201 SER
B 671 GLU
Psi
B 340 VAL
A 809ALEU
888 ARG
B 677 SER
0
202 ILE
B 80AVAL
A194
652
ASP
A B759
ASN
LEU
B 547 CYS
A 572 THR
B 412 LYS
A 515 TYR
0
A 411 ALA
A 528 SER
B 346 ASP
617LEU
CYS
BB 341
A 570 ASP
B 240 ASN
A 82 LYS B 673 SER
A 514 LEU
BA636
908ARG
PHE
B 167 ILE
B 157 VAL
A 656 VAL
A 504 GLN
B B
180195
MET
THR
-180
A 708 ASP
A 527 ILE
-180
0
Phi
180
Pre-proline
180
A 835 ILE
-180
B 253 LYS
-180
0
Phi
180
Glycine
180
A 371 GLY
A 597 GLY
B 649 GLY
B 362 LEU
Psi
B 590 GLN
Psi
A 757 ILE
A 573 GLY
B 75 GLY
A 287 GLY
B 684 GLU
B 168 SER
0
0
B 538 GLY
A 487 LEU
B 162 SER
685
ASN
AAB749
84SER
SER
A 450 TYR
A 954 GLY
A 348 GLY
B 623 GLU
-180
-180
0
Phi
-180
180
Trans proline
180
-180
0
Phi
180
Phi
180
Cis proline
180
B 57 PRO
A 554 PRO
Psi
Psi
B 85 PRO
0
0
B 169 PRO
B 176 PRO
-180
B 407 PRO
A 420 488
PROPRO
B 624AA
PRO
69 PRO
-180
-180
77.8% (1135/1458) of all residues were in favored (98%) regions.
93.9% (1369/1458) of all residues were in allowed (>99.8%) regions.
A 954 GLY (56.8, -78.1)
B 57 PRO (-33.6, 151.8)
There were 89 outliers (phi, psi):
A 62 SER (-62.6, 43.8)
A 69 PRO (-40.4, -165.6)
B 75 GLY (31.9, 87.0)
B 76 ASP (-64.9, 83.1)
B 79 GLN (43.3, 14.5)
A 82 LYS (-50.6, -91.3)
A 194 LYS (-176.1, -11.6)
B 80 VAL (29.3, 107.8)
B 84 SER (-47.1, -83.1)
0
Phi
180
-180
0
B 70 SER (-51.0, 96.9)
A 201 SER (-166.6, -74.4)
A 202 ILE (55.1, 110.4)
B 85 PRO (-61.1, 77.2)
B 157 VAL (-146.3, -76.4)
A 287 GLY (23.3, 61.6)
A 348 GLY (-62.9, -88.5)
B 162 SER (-2.6, -76.4)
B 167 ILE (5.4, -67.8)
A 371 GLY (58.8, 146.8)
A 411 ALA (176.5, -23.3)
A 420 PRO (-53.2, -159.9)
B 168 SER (148.8, 41.2)
B 169 PRO (-64.5, -84.1)
B 172 ALA (-64.5, 18.2)
A 450 TYR (-61.7, -94.7)
A 487 LEU (-162.4, -43.7)
B 176 PRO (-138.6, -139.2)
B 180 MET (-78.8, -149.1)
A 488 PRO (-33.7, -160.0)
A 491 LEU (-61.8, 88.3)
B 194 LEU (59.9, 99.3)
B 195 THR (-66.1, -154.2)
A 504 GLN (-64.1, -142.8)
A 514 LEU (-68.9, -100.4)
B 199 GLN (-53.5, 98.4)
B 240 ASN (-38.5, -85.9)
A 515 TYR (-47.3, -15.9)
A 517 ARG (-59.8, 91.3)
B 253 LYS (-58.1, -178.8)
B 340 VAL (-59.6, 88.2)
A 527 ILE (-170.6, -159.7)
A 528 SER (177.2, -45.8)
B 341 LEU (169.0, -66.0)
B 346 ASP (176.7, -58.0)
A 554 PRO (-13.4, 130.2)
A 570 ASP (-21.6, -73.4)
A 571 THR (-50.8, 99.7)
B 362 LEU (93.9, 112.2)
B 377 ASN (39.9, 25.0)
B 407 PRO (-81.1, -145.7)
A 572 THR (40.8, 89.2)
A 573 GLY (-18.8, 90.0)
B 409 GLU (-31.3, 143.4)
B 412 LYS (40.3, 80.3)
A 597 GLY (-32.1, 115.2)
A 652 ASP (67.5, 103.9)
B 538 GLY (167.3, -17.3)
B 546 ASP (-171.2, 5.4)
A 656 VAL (-77.9, -130.7)
A 659 ASN (-67.1, 39.2)
B 547 CYS (96.3, 96.1)
B 549 CYS (-45.9, 163.4)
A 685 ASN (-53.9, -82.0)
A 688 LYS (-40.8, 161.9)
B 558 CYS (89.9, 32.5)
B 576 SER (52.9, 4.9)
A 708 ASP (74.7, -144.6)
A 749 SER (-58.2, -82.6)
B 590 GLN (-31.3, 87.7)
B 617 CYS (174.9, -63.3)
A 757 ILE (40.0, 93.3)
A 759 ASN (49.5, 102.4)
A 809 LEU (82.0, 57.7)
B 623 GLU (63.5, -172.6)
B 624 PRO (-65.5, -166.0)
B 636 ARG (-75.3, -106.8)
A 835 ILE (-62.5, -156.6)
A 888 ARG (110.8, 55.6)
B 649 GLY (-41.3, 107.6)
B 671 GLU (175.7, 84.0)
A 905 THR (-68.1, 33.2)
A 908 PHE (-70.0, -106.3)
B 673 SER (3.8, -95.8)
B 677 SER (-170.2, 56.8)
A 910 ASN (-66.2, 18.3)
B 680 TYR (-32.6, 106.1)
B 684 GLU (87.3, 57.5)
http://kinemage.biochem.duke.edu
Lovell, Davis, et al. Proteins 50:437 (2003)